263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Jun 15, 2023•40 min
Episode description
Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen's boardroom scandal has roiled a company that was supposed to be entering a new era.
For the best experience, listen in Metacast app for iOS or Android
